Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Bristol-Myers Squibb Company Ce
- Market Cap
- Unavailable
- Volume
- 9.5M
About
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
Quick stats
Shares outstanding2.0B
Computed float2.0B
Float / shares99.9%
Key info
SectorHealthcare
IndustryDrug Manufacturers - General
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000014272
Websitehttp://www.bms.com
AI Summary
AI-generated1/50
criticalbullishfda approval
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Bristol Myers Squibb received accelerated FDA approval for ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma.
This marks the first approval of a CELMoD therapy, a new class of cereblon-modulating protein degraders, based on Phase 3 data showing MRD-negative complete response rates of 41% versus 21% for the standard of care.
Full approval is contingent upon verification of clinical benefit in confirmatory trials, though the immediate availability provides a new option for patients as early as first relapse.
Red flags
- Boxed warnings for embryo-fetal toxicity and serious venous/arterial thromboembolism
- High incidence of neutropenia (90.2%) and infections (78.9%) in clinical trials
- Fatal adverse reactions occurred in 4.9% of patients receiving ZENBEXUS
- Full approval contingent on confirmatory trial results for clinical benefit